← Research library

Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays

Lab research · 1999

What was studied
Isolated preparations from guinea pig, hamster, mouse, rat and rabbit
Main finding
Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.

[L-Ala²] analogue · 19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM

Reported findings and study design

Isolated animal tissues comparing Dalargin analogues at opioid-receptor assay sites.

Population or model Isolated preparations from guinea pig, hamster, mouse, rat and rabbit

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
[L-Ala²] analogue19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM
[Met⁵] analogueNaloxone KB 5.5 nM
DalarginethylamideNaloxone KB 5.0 nM
N-methyl-[L-Phe⁴]-dalarginamideδ/μ ratio 0.00053; naloxone KB 2.6 nM
[D-Phe⁴] amide analoguesInactive in the reported assays

Each potency/ratio belongs to a particular analogue; the KB figures concern naloxone antagonism, not a Dalargin human affinity or dose.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Animal-tissue bioassays, not a human efficacy or safety trial.
  • Dalargin analogues are not interchangeable with the parent peptide.

Source details

Selected source text and metadata checked; full risk-of-bias review pending.

Selected text reviewed

Sources checked

Citation

In vitroEnglish abstract

N. Pencheva, J. Pospišek, L. Hauzerova, T. Barth, P. Milanov. Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays British Journal of Pharmacology. 128(3):569–576

Study source ↗ · DOI 10.1038/sj.bjp.0702825 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards